Jul 02, 2020
Exercise of Over-allotment Option and End of the Stabilization Period
Jun 30, 2020
Number of Shares and Votes in Calliditas Therapeutics
Jun 25, 2020
Bulletin From the Annual General Meeting of Calliditas Therapeutics AB (publ)
Jun 24, 2020
Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market
Jun 22, 2020
CEO Renée Aguiar-Lucander Exercises Warrants and Invests SEK 15.7m (Appr. USD 1.7m) in Calliditas
Jun 12, 2020
Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market
Jun 05, 2020
Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States
Jun 01, 2020
Calliditas Therapeutics Launches US IPO Roadshow and Targets a Capital Raise of MUSD 75
May 14, 2020
Calliditas Publicly Files Registration Statement With SEC for a Proposed Initial Public Offering in the United States
May 14, 2020
Calliditas Therapeutics: Interim Report Q1, 2020
Apr 27, 2020
Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic
Apr 01, 2020
Calliditas Strengthens its US Commercial Organization
Mar 30, 2020
Calliditas Moves its Annual General Meeting 2020 to June 25
Feb 14, 2020
Calliditas Therapeutics - Year-End Report 2019
Jan 22, 2020
Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN
Jan 09, 2020
Calliditas Submits Draft Registration Statement for the Listing of ADSs in the U.S.
Dec 23, 2019
The pivotal Phase 3 Clinical Trial NefIgArd Part A Fully Recruited
Dec 19, 2019
Completion of Recruitment of Part A of the Neflgard Pivotal Phase 3 Clinical Trial by Year End
Dec 17, 2019
China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines
Nov 14, 2019
Interim Report Q3, 2019